Zak, D.E. et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc. Natl. Acad. Sci. USA 109, E3503-E3512

Seattle Biomedical Research Institute, Seattle, WA 98109.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 11/2012; 109(50). DOI: 10.1073/pnas.1208972109
Source: PubMed


To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.

Download full-text


Available from: Joleen A Borgerding, Mar 06, 2014
110 Reads
  • Source
    • "Second, that the use of different vaccine components and/or their order of administration can be used to tailor resulting immunity, both quantitatively and qualitatively [7], [8]. Although there is clear evidence to support the former concept [9], [10], our understanding of how to tailor vaccine-elicited immunity through the heterologous use of different vaccine components is still very much in its infancy [11]–[15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Using a unique vaccine antigen matched and single HIV Clade C approach we have assessed the immunogenicity of a DNA-poxvirus-protein strategy in mice and rabbits, administering MVA and protein immunizations either sequentially or simultaneously and in the presence of a novel TLR4 adjuvant, GLA-AF. Mice were vaccinated with combinations of HIV env/gag-pol-nef plasmid DNA followed by MVA-C (HIV env/gag-pol-nef) with HIV CN54gp140 protein (+/-GLA-AF adjuvant) and either co-administered in different muscles of the same animal with MVA-C or given sequentially at 3-week intervals. The DNA prime established a population of B cells that were able to mount a statistically significant anamnestic response to the boost vaccines. The greatest antigen-specific antibody response was observed in animals that received all vaccine components. Moreover, a high proportion of the total mucosal IgG (20 - 50%) present in the vaginal vault of these vaccinated animals was vaccine antigen-specific. The potent elicitation of antigen-specific immune responses to this vaccine modality was also confirmed in rabbits. Importantly, co-administration of MVA-C with the GLA-AF adjuvanted HIV CN54gp140 protein significantly augmented the antigen-specific T cell responses to the Gag antigen, a transgene product expressed by the MVA-C vector in a separate quadriceps muscle. We have demonstrated that co-administration of MVA and GLA-AF adjuvanted HIV CN54gp140 protein was equally effective in the generation of humoral responses as a sequential vaccination modality thus shortening and simplifying the immunization schedule. In addition, a significant further benefit of the condensed vaccination regime was that T cell responses to proteins expressed by the MVA-C were potently enhanced, an effect that was likely due to enhanced immunostimulation in the presence of systemic GLA-AF.
    PLoS ONE 01/2014; 9(1):e84707. DOI:10.1371/journal.pone.0084707 · 3.23 Impact Factor
    • "A modified vaccinia virus Ankara (MVA) was well tolerated and produced a good safety profile in humans infected with HIV-1 undergoing highly active anti-retroviral therapy (HAART). Additional viral-vector technologies that are currently being pursued for vaccine delivery include proxy-viruses, measles virus, vesicular stomatitis virus, HSV and alpha virus among others93. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The pure recombinant and synthetic antigens used in modern day vaccines are generally less immunogenic than older style live/attenuated and killed whole organism vaccines. One can improve the quality of vaccine production by incorporating immunomodulators or adjuvants with modified delivery vehicles viz. liposomes, immune stimulating complexes (ISCOMs), micro/nanospheres apart from alum, being used as gold standard. Adjuvants are used to augment the effect of a vaccine by stimulating the immune system to respond to the vaccine, more vigorously, and thus providing increased immunity to a particular disease. Adjuvants accomplish this task by mimicking specific sets of evolutionary conserved molecules which include lipopolysaccharides (LPS), components of bacterial cell wall, endocytosed nucleic acids such as dsRNA, ssDNA and unmethylated CpG dinucleotide containing DNA. This review provides information on various vaccine adjuvants and delivery vehicles being developed to date. From literature, it seems that the humoral immune responses have been observed for most adjuvants and delivery platforms while viral-vector, ISCOMs and Montanides have shown cytotoxic T-cell response in the clinical trials. MF59 and MPL® have elicited Th1 responses, and virus-like particles (VLPs), non-degradable nanoparticle and liposomes have also generated cellular immunity. Such vaccine components have also been evaluated for alternative routes of administration with clinical success reported for intranasal delivery of viral-vectors and proteosomes and oral delivery of VLP vaccines.
    The Indian Journal of Medical Research 11/2013; 138(5):779-95. · 1.40 Impact Factor
  • Source
    • "Early molecular signatures also predicted Ab responses to trivalent inactivated influenza vaccine [166]. A systems approach was recently used to define innate immune signatures in recipients of MRK Ad5/HIV vaccine: upregulation of genes associated with inflammation, interferon responses and myeloid cell trafficking was observed in PBMC within 24 hours of vaccination and was accompanied by marked elevations in circulating proinflammatory cytokines [167]. It is noteworthy that these changes were highly attenuated by pre-existing NAbs to Ad5, and the innate response profile predicted the magnitude of subsequent HIV-specific CD8+ T cell responses. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase IIb trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.
    Retrovirology 07/2013; 10(1):72. DOI:10.1186/1742-4690-10-72 · 4.19 Impact Factor
Show more